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Cell morphology and gene expression alterations proved 
particularly sensitive for environmental carcinogen iden-
tification. Composite scores for the carcinogens’ adverse 
effects revealed that this approach could identify both DNA-
reactive and non-DNA reactive carcinogens in vitro. The 
richer datasets generated proved that the holistic evaluation 
of integrated phenotypic alterations is valuable for effective 
in vitro risk assessment, while also supporting animal test 
replacement. Crucially, the study offers valuable insights 
into the mechanisms of human carcinogenesis resulting from 
exposure to chemicals that humans are likely to encoun-
ter in their environment. Such an understanding of cancer 
induction via environmental agents is essential for cancer 
prevention.
Keywords Carcinogenesis · In vitro · Genotoxicity · 
Multiple-endpoint · Carcinogenicity testing
Introduction
Cancer is the second leading cause of mortality worldwide, 
with the number of new cases projected to rise by 70% over 
the next two decades (Stewart and Wild 2017). It has been 
demonstrated that 70–90% of human cancers are induced via 
exposure to environmental agents (Wu et al. 2016). Com-
mon routes of exposure to chemical carcinogens include the 
consumption of alcoholic beverages, tobacco smoking and 
occupational exposure.
Cancer may be initiated via both genotoxic and non-
genotoxic mechanisms (Hanahan and Weinberg 2000, 
2011). Most identified carcinogens fall within the initial 
group of genotoxic carcinogens (GCs), these triggering 
DNA mutation or chromosomal aberration (Hernan-
dez et  al. 2009). However, non-genotoxic carcinogens 
Abstract Human exposure to carcinogens occurs via a 
plethora of environmental sources, with 70–90% of cancers 
caused by extrinsic factors. Aberrant phenotypes induced by 
such carcinogenic agents may provide universal biomark-
ers for cancer causation. Both current in vitro genotoxicity 
tests and the animal-testing paradigm in human cancer risk 
assessment fail to accurately represent and predict whether a 
chemical causes human carcinogenesis. The study aimed to 
establish whether the integrated analysis of multiple cellular 
endpoints related to the Hallmarks of Cancer could advance 
in vitro carcinogenicity assessment. Human lymphoblastoid 
cells (TK6, MCL-5) were treated for either 4 or 23 h with 
8 known in vivo carcinogens, with doses up to 50% Rela-
tive Population Doubling (maximum 66.6 mM). The adverse 
effects of carcinogens on wide-ranging aspects of cellular 
health were quantified using several approaches; these 
included chromosome damage, cell signalling, cell mor-
phology, cell-cycle dynamics and bioenergetic perturbations. 
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(NGCs), which constitute 10–20% of carcinogens (Bartsch 
and Malaveille 1989), demonstrate broader mechanistic 
variety, altering epigenetics, the endocrine system, apop-
totic signalling, cell proliferation, and/or gap-junctional 
intercellular communication (Melnick et al. 1996; Uehara 
et al. 2008; Williams 2001). Furthermore, simultaneous 
alteration of multiple pathways is often required to prompt 
non-genotoxic oncogenesis (Guyton et al. 2009). There-
fore, to understand an unknown carcinogenic mechanism, 
whether genotoxic or non-genotoxic, multiple-endpoint 
analysis is required. The eventual result, cancer develop-
ment, combines uncontrolled cellular proliferation with 
genome instability, angiogenesis, and metastasis to distant 
tissues. Such characteristics have been defined as “Hall-
marks of Cancer” (Hanahan and Weinberg 2000).
Carcinogenicity testing is a crucial aspect of compound 
development and safety assessment in pharmaceutical, 
food and agricultural industries. Such testing includes 
short-term in vitro assays, short-term in vivo assays, and 
the 2-year rodent bioassay (Kirkland et al. 2005). Ban-
ning of in vivo cosmetics testing in 2013 has increased 
dependence on in vitro tests, contributing to expense, time 
and ethical benefits. It is argued, particularly as part of 
Toxicity Testing in the 21st Century (Adeleye et al. 2015; 
Council 2007), that the in vitro shift may also improve 
human relevance: animal models often fail to represent 
human physiology, genetics and metabolism (Long 2007). 
Furthermore, recognition of the importance of the 3Rs 
(Reduction, Replacement and Refinement of animals in 
research) Principle is increasing. Development of more 
sophisticated in vitro assays is, therefore, key to future 
compound development.
Genotoxicity assays represent preliminary carcinogenic-
ity testing, with the standard in vitro genotoxicity battery 
including the Ames test, micronucleus assay and the chro-
mosomal aberration assay (Muller et al. 1999). Despite this 
battery achieving high sensitivity, factors such as variation 
between cell lines, time points, and incomplete compound 
metabolism reduce the specificity of results (Kirkland et al. 
2005). An additional inadequacy of in vitro carcinogenicity 
assessment is the lack of approved tests for the identification 
of non-genotoxic carcinogens. For example, one currently 
available approach is the use of Cell Transformation Assays 
(CTAs), which utilises the phenotypic transformation of 
stem cells as a marker of carcinogenicity (Kerckaert et al. 
1996). However, disadvantages include these assays’ sub-
jectivity, qualitative results and lack of mechanistic insight. 
Cells used are often derived from rodent embryos (e.g., 
Syrian hamster embryo, mouse BALBc 3T3 and C3H/10T 
cells), and so it is unclear whether these tests can be consid-
ered to be true in vitro tests, resulting in 3Rs-related impli-
cations. Therefore, it is clear that more informative in vitro 
tests with greater specificity are urgently required.
The objective of this study was to improve the in vitro-
based detection of carcinogenic mechanisms, including dif-
ferentiation between GCs and NGCs by combining multiple 
cellular and molecular endpoints.
The test compounds were selected for their broad range 
of carcinogenic mechanisms (Table 1), allowing the appli-
cability of the approach for identifying carcinogens to be 
assessed. The genotoxicity and mutagenicity of alkylating 
agents methyl methanesulfonate (MMS) and N-methyl-
N-nitrosourea (MNU) is well established, with these pro-
ducing differing profiles of methyl DNA adducts (Beranek 
1990; Doak et al. 2007). Pro-oxidant hydrogen peroxide 
 (H2O2) produces lesions such as 8-oxoguanine (Finnegan 
et al. 2010), whereas acetaldehyde induces lesions such as 
N2-ethyl-2′-deoxyguanosine (Brooks and Theruvathu 2005).
The NGCs were also selected for their diverse mecha-
nisms of carcinogenesis; 2,3,7,8-tetrachloro-dibenzo-para-
dioxin (TCDD) and bis-2-ethylhexyl phthalate (DEHP) are 
both well-known endocrine disruptors and tumour promoters 
(Bock and Köhle 2005; Caldwell 2012; Casals-Casas and 
Desvergne 2011). Heavy metal compound nickel chloride 
 (NiCl2) induces oxidative stress. The carcinogenic mecha-
nism of methyl carbamate (MC) is less well-characterised, 
although MC may elicit effects via bioaccumulation (Ioan-
nou et al. 1988).
The compounds’ relevance to human environmental 
exposure was a further justification (Table 1). Three of the 
chemicals, MMS, DEHP and MC, are also included on a 
recommended list of genotoxic and non-genotoxic chemicals 
for the assessment of the performance of new or improved 
genotoxicity tests (Kirkland et al. 2016).
Integrating multiple endpoints alongside genotoxicity 
testing was expected to provide considerably more mech-
anistic information to support the testing paradigm. To 
achieve this, the analysis of known in vivo carcinogens was 
performed (Table 1), with endpoints including micronu-
cleus induction, cell-cycle alterations, cell signalling abnor-
malities, mitochondrial perturbations and cell morphology 
alterations. These endpoints cover 4 of the 6 original cancer 
hallmarks (Hanahan and Weinberg 2000). Results from this 
study have been integrated to define both genotoxic and non-
genotoxic mechanisms with the future objective of develop-
ing a fully multiplexed in vitro assay for high-throughput 
analysis of carcinogenic potential of unknown agents.
Materials and methods
Chemicals
Test chemicals were purchased from Sigma-Aldrich (Haver-
hill, UK), with the exception of MNU (Fluorochem, Pasa-
dena, CA, USA) and TCDD (LGC Standards, Middlesex, 
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UK), and stored according to the manufacturer’s instruc-
tions.  H2O2, MMS, MC and  NiCl2 were dissolved/diluted 
in  dH2O, whereas MNU and DEHP were dissolved/diluted 
in dimethyl sulfoxide (DMSO) (Thermo Fisher Scientific, 
Loughborough, UK).
Cell culture
The human lymphoblastoid cell lines, TK-6 and MCL-5 
(ECACC), were cultured in RPMI 1640 Medium (Life 
Technologies, Paisley, UK) supplemented with 10% donor 
horse serum and 1% l-glutamine (both Life Technologies). 
Hygromycin B was used to supplement MCL-5 cultures 
(TCDD only) to support uptake of plasmids. The cells were 
maintained in culture between 1  ×  105 and 1  ×  106 cells/
ml. For all studies, cells were seeded at a density of 1 × 105 
cells/ml and cultured for 24 h prior to chemical treatment 
(37 °C, 5%  CO2).
Cytokinesis blocked micronucleus assay
Chromosome damage was analysed using the cytokinesis 
blocked micronucleus (CBMN) assay. The protocol for 
Metafer analysis is presented in (Seager et al. 2014). Time-
points used were either 4 h treatment + 23 h recovery, or 
23 h treatment + 23 h recovery. A total of 9000 binucle-
ate cells were scored per treatment per replicate. Relative 
population doubling (RPD) (%) (Fellows et al. 2008; Lorge 
et al. 2008) was measured in parallel, with < 50% reduction 
in RPD relative to the vehicle control aimed for, in line with 
OECD requirements.
Protein isolation and immunoblotting
To investigate p53 and phospho-p53 expression following 
treatment, protein isolation and immunoblotting were per-
formed. The method followed is detailed in (Brusehafer et al. 
2014).
mRNA microarrays
mRNA microarray chip technology (Illumina, Cambridge, 
UK) was used to initially measure genome-wide transcrip-
tomic changes induced by MMS, DEHP and MC at 4 and 
23 h. A shortlist of genes for further qRT-PCR analysis was 
generated (Supplementary File 1). RNA was extracted from 
treated cultures using the RNeasy Mini Kit (Qiagen, Man-
chester, UK) following the manufacturer’s protocol. Micro-
array analysis was performed by Central Biotechnology Ser-
vices (Cardiff University, Cardiff, UK) using an Illumina 
platform bead express model, with a total of 25,202 Illu-
mina probes for known genes. Genes selected for follow-up 
qRT-PCR analysis were Cyclin-dependent kinase inhibitor Ta
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1A (CDKN1A), Choline kinase alpha (CHKA) and Serine/
threonine protein kinase (SGK1).
Gene expression analysis
qRT-PCR was completed for the aforementioned genes; 
the protocol is detailed in (Brusehafer et al. 2014). Primer 
sequences: CDKN1A Forward: 5′GAC TCT CAG GGT CGA 
AAA CG3′, Reverse: 5′GGA TTA GGG CTT CCT CTT GG3′. 
CHKA Forward: 5′TGC AGA TGA GGT CCT GTA ATA AAG 
A3′, Reverse: 5′TTT TGG CCC AAG TGA CCT CT3′. SGK1 
Forward: 5′GAA CCA CGG GCT CGT TTC TAT3′, Reverse: 
5′GCA GGC CAT ACA GCA TCT CAT3′. ACTB Forward: 
5′GAT GGC CAC GGC TGC TTC 3′, Reverse: 5′TGC CTC 
AGG GCA GCG GAA 3′. A CFX Connect Real-time System 
and CFX Manager software (both BioRad, Oxford, UK) 
were used.
Cell‑cycle analysis
Flow cytometry was used to assess nucleated cells in G1, S 
and G2, where samples were processed using the In Vitro 
MicroFlow Micronucleus Analysis Kit (Litron Laboratories, 
Rochester, NY, USA), as per the manufacturer’s instruc-
tions. Samples were analysed using the BD Facs Aria Flow 
Cytometer (BD Biosciences, Wokingham, UK), with Fac-
sDiva software (BD Biosciences). Appropriate gating was 
applied to determine the cell-cycle phase. A total of 36,000 
events were analysed across 3 replicates per dose.
Cell morphology analysis
Following treatment, cells were washed with PBS, fixed for 
15 min with 4% paraformaldehyde and stained for 30 min 
with 2.5 µg/ml Hoechst 33,342 (Life Technologies). Bright-
field and Hoechst images were acquired utilising the INCell 
Analyzer 2000 or 2200 (144 fields/well) (GE Healthcare, 
Cardiff, UK). Image analysis was performed with Matlab 
Version 7.12.0 (R2011a). Following this, an equal number 
of cell and nuclear area results were selected from a group 
of control replicates. These control groups were segregated 
depending on experimental conditions, vehicle and cell 
type. The smallest 20% of the population were then classi-
fied as ‘Lowest’, the next 20% as ‘Low’ and so on to clas-
sify ‘Medium’, ‘High’ and ‘Highest’ cellular/nuclear area 
thresholds (these being quintiles) (Supplementary File 2).
Bioenergetics studies
The Seahorse Bioanalyzer (Agilent, Cheadle, UK) was used 
to measure bioenergetic flux in control and treated samples, 
to establish whether chemicals influenced this endpoint. 
Seahorse microplates (Agilent) were coated using CellTak 
reagent (Corning, UK). Cells pre-treated with the appropri-
ate chemical for 4 or 23 h were transferred to coated micro-
plates (400,000 cells/well) 1 h prior to assay commence-
ment, with gentle centrifugation at 20×g to aid adhesion. 
Unbuffered Seahorse medium adjusted to pH 7.5 (Agilent) 
was used. The plate was then transferred to a non-CO2 incu-
bator for 25 min prior to addition of 425 µl medium and 
then incubated for a further 35 min to promote equilibra-
tion. Following routine calibration of the machine, oxygen 
consumption rate (OCR) and extracellular acidification rate 
(ECAR) were measured simultaneously using the  XFe24 
Seahorse Bioanalyzer to assess basal versus drug-induced 
perturbations.
ToxPi™ graphical user interface
The Toxicological Prioritization Index (ToxPi™) Graphi-
cal User Interface (GUI) is a publically available visualiza-
tion tool developed at the University of North Carolina that 
enables the integration of multiple sources of evidence on 
exposure and/or safety (Reif et al. 2010, 2013). The soft-
ware may be accessed via http://comptox.unc.edu/toxpi.php. 
Within the pie chart, the length of the “slice” radius was 
proportional to the magnitude of the change relative to the 
vehicle control. The concentration of chemical inducing a 
50% reduction in RPD relative to the vehicle control, or the 
highest concentration administered, was used to generate 
fold-change values relative to the control. Slices of the pie 
chart were weighted according to the nature of the endpoint. 
Specifically, slice weightings were allocated depending on 
the number of endpoints measured by a single technique. All 
individual techniques (e.g., qRT-PCR, cell-cycle analysis) 
were weighted equally. Therefore, if one technique measured 
two or three endpoints, the sum of the weightings of these 
individual endpoints would be equal to the techniques with a 
single measured endpoint (i.e., CBMN assay and Seahorse). 
The square root of all values (with the exception of cell and 
nuclear area) was taken and scores were scaled sufficiently to 
enable clear “slice” visualisation for endpoint groups.
Statistical analysis
Three biological replicates (except where indicated) 
were performed on separate days, with separate vials of 
cells/chemicals. Error bars represent standard deviation. 
Dose–Response Modelling with Smoothing Splines (DRS-
MOOTH, Mutait.org), was used to perform the statistical 
analysis, to identify statistically significant increases or 
decreases for treated samples relative to the vehicle control 
(Avancini et al. 2016). A mean-centering approach was 
used for the qRT-PCR data (Willems et al. 2008) prior 
to statistical analysis using DRSMOOTH. Outcomes of 
p ≤ 0.05 for two-sided tests were deemed statistically 
Arch Toxicol 
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significant. For the analysis of data generated by the Sea-
horse Bioanalyzer, SPSS was used to perform hierarchical 
cluster analysis.
Results
The study of the mechanisms by which chemical com-
pounds in the environment may induce cancer is essen-
tial. Many in vitro-based genotoxicity tests currently only 
assess a single genotoxic endpoint, thus increasing the 
possibility of misleading predictive data. Negative results 
in genotoxicity and mutation-based assays for chemicals 
do not always equate to the chemicals being non-carcin-
ogens, considering that a subset of carcinogens are non-
genotoxic. Therefore, it is emerging that the use of more 
sophisticated, multiple-endpoint in vitro approaches will 
better inform safety assessment while minimizing labo-
ratory animal use. Multiple endpoints allow a holistic 
overview of chemicals’ effects on cells, leading to greater 
mechanistic understanding for both genotoxic and non-
genotoxic carcinogens. Here, a novel integrated test strat-
egy was developed using a variety of carcinogenicity-
associated endpoints.
The GCs caused genotoxicity
Genotoxicity induction was measured using a high-powered 
CBMN assay (Fig. 1). Cells were treated with test chemical 
for 4 h (+ 23 h recovery) initially to identify no-observed 
effect levels (NOELs) and lowest observed effect levels 
(LOELs) for micronucleus (MN) dose–responses. If no 
significant increases in genotoxicity (i.e., LOELs) were 
observed after 4 h + 23 h, 23 h treatment was performed 
(+ 23 h recovery).  H2O2 was the only positive chemical after 
4 h (Fig. 1c). The three other GCs, acetaldehyde, MMS and 
MNU, did not produce significant changes in genotoxicity 
after 4 h (data not shown). At 23 h, however, all of these 
chemicals caused MN induction at concentrations of ≥ 500, 
6.4 and 2.9 µM, respectively (Fig. 1).
No NGCs tested, DEHP, MC,  NiCl2, and TCDD, induced 
significant MN increases at any test concentrations after 4 
or 23 h. As TCDD is known to induce enzymes such as 
the Cytochrome P450  s (Hukkanen et  al. 2000), it was 
tested using the metabolically competent MCL-5 cell line 
(Fig. 1h); here, no significant increases in MN frequency 
were observed (p > 0.05). MC was the only chemical not 
to approach 50% cytotoxicity. Dose selection for MC was 
performed based on literature, hence the maximum concen-
tration exceeded the recommended 10 mM (Kim et al. 2005; 
Kwon et al. 2007; Mitchell et al. 1997).
p53 and phospho‑p53 increased in response to all 
genotoxic and one non‑genotoxic chemical
p53 is an important node in the DNA Damage Response 
(DDR) with a central role in carcinogenesis (Banin et al. 
1998). p53 and phospho-p53 protein levels were assessed 
using Western blotting (immunoblotting) and the relevant 
bands on images quantified using densitometry (Fig. 2). 
For GCs, MNU and  H2O2 induced p53 and phospho-p53 at 
concentrations above their respective genotoxicity LOELs 
(Fig. 2c, d). MMS and acetaldehyde also increased p53 and 
phospho-p53, although these changes were non-significant 
(Supplementary File 3). As Western blotting is only semi-
quantitative, it is plausible that such changes indicate true 
biological effects, despite lacking significance. Treatment 
with the NGC  NiCl2 also elevated p53 levels, despite this 
chemical not inducing genotoxicity (Fig. 1).  NiCl2, however, 
did not cause a dose-dependent increase, with only 100 µM 
increasing p53 abundance. Interestingly,  NiCl2 was the only 
chemical tested to significantly induce reactive oxygen spe-
cies (ROS), (Supplementary File 4), possibly explaining this 
unusual result. DEHP, MC and TCDD did not cause sig-
nificant changes in p53 or phospho-p53 protein abundance 
(Supplementary File 3).
Carcinogens altered p21, CHKA and SGK1 mRNA 
expression
Whole-genome RNA microarrays were used to determine 
a small panel of target genes altered by DEHP, MC and 
MMS for further, more detailed gene expression studies by 
qRT-PCR. Following microarray analysis, three “carcino-
genesis biomarker” genes were taken forward for further 
investigation: CDKN1A, CHKA and SGK1 (highlighted in 
Supplementary File 1). CDKN1A encodes  p21Cip/Waf; due 
to its relevance to cancer, this gene was selected indepen-
dently of the microarray data. The other two genes, CHKA 
and SGK1, were selected based on the criteria outlined in 
Supplementary File 1, Tab 2. CHKA is known to be over-
expressed in human tumours (de Molina et al. 2002), while 
SGK1 regulates survival and growth in colorectal cancers 
(Lang et al. 2010).
Two GCs, MMS and MNU, induced clear dose-dependent 
increases in mRNA transcribed from the p21 gene (Fig. 3c, 
d). Acetaldehyde stimulated a biphasic dose-response, with 
an increase at 250 µM, followed by a decrease at 1000 µM. 
Indeed, all GCs increased p21 expression, despite levels 
of p21 induced by  H2O2 lacking significance. It was noted 
that acetaldehyde, MMS and MNU produced significant 
increases in expression of p21-encoding mRNA at concen-
trations below the MN LOELs (Fig. 1), a phenomenon not 
observed with Western blotting for p53 activation. MMS 
and acetaldehyde both significantly altered CHKA gene 
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Fig. 1  The CBMN assay (4 or 23 h exposure + 23 h recovery) was 
used to determine whether test compounds were genotoxic. Micro-
nucleated cells (%) (black lines) and Relative Population Doubling 
(RPD) (%) (grey lines) data are displayed for eight chemicals (n = 3 
for a–d, n = 2 for e–h). Data for NGCs are presented in duplicate due 
to two replicates being sufficient to confirm the lack of MN-induction 
for these chemicals. Statistically significant changes in percentage 
cells relative to the vehicle control are denoted by *, where *p ≤ 0.05, 
**p ≤ 0.01 and ***p ≤ 0.001. For RPD, a Beckman Coulter Coun-
ter was used to count cells prior to dosing and following the recovery 
period
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expression relative to the control (Fig. 3, Supplementary File 
3).  H2O2 and MNU significantly altered SGK1 expression at 
the highest test concentrations (Fig. 3). With the exception 
of MMS, all GCs increased SGK1 mRNA expression above 
control levels (Fig. 3, Supplementary File 3).
NGCs also demonstrated a capacity to alter gene expres-
sion (Fig. 3e–h). Three NGCs significantly altered p21 
mRNA expression: DEHP,  NiCl2 and MC (Fig. 3).  NiCl2 
produced a clear dose-dependent increase in p21 mRNA 
(Fig.  3e). Interestingly, MC significantly reduced both 
p21 and SGK1 mRNA levels, in contrast to the GCs that 
increased their expression. Two NGCs, MC and TCDD, sig-
nificantly altered CHKA expression (Fig. 3). However, all 
NGCs increased CHKA mRNA expression (Supplementary 
File 3). MC and TCDD were also the only NGCs to signifi-
cantly alter SGK1 levels. In summary, all eight chemicals 
caused statistically significant dysregulation of at least one 
of the genes tested.
Four test chemicals induced arrest at G2 phase 
of the cell‑cycle
As the cell-cycle is a crucial link to the cancer hallmark of 
uncontrolled proliferation, the distribution of nucleated cells 
in G1, S and G2 cell-cycle phases immediately following 
4 or 23 h treatments was measured using flow cytometry 
(Fig. 4). All GCs stimulated statistically significant and, 
in the case of MMS and acetaldehyde, dose-dependent, 
increases in cells in the G2 phase after 23 h, indicating G2 
arrest (Fig. 4a–d). These G2 increases were accompanied 
by statistically significant reductions in the two other cell-
cycle categories, G1 and S phase. The GC  H2O2 did not 
induce any statistically significant changes in the cell-cycle 
Fig. 2  p53 and phospho-p53 expression as determined by Western 
blotting for 4 or 23 h exposure. a, b Representative examples of blot 
images for p53, phospho-p53 (Both 53  kDa) and ß-actin (45  kDa). 
These examples were from  H2O2 treatment. c–e Densitometry 
graphs are presented for chemicals that caused significantly altered 
expression of p53 and/or phospho-p53 (n  =  3). Statistically signifi-
cant changes in fold change expression are denoted by red *, where 
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Arrows above specific con-
centrations correspond to the MN LOEL, or concentration nearest to 
the LOEL, for the carcinogens (Fig. 1), where applicable (colour fig-
ure online)
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Fig. 3  Relative expression of mRNA of the CDKN1A, CHKA and 
SGK1 genes as determined by qRT-PCR (n ≥ 3) for 4 or 23 h expo-
sure. Statistically significant changes in fold change gene expression 
relative to the vehicle control are denoted by *, where *p  ≤  0.05, 
**p ≤ 0.01 and ***p ≤ 0.001. Arrows above selected concentrations 
correspond to the MN LOEL, or concentration nearest to the LOEL, 
for carcinogens, where applicable
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Fig. 4  Cell cycle analysis was performed using flow cytometry for 
samples treated for 23 h (n = 3). A historical vehicle (either  H2O or 
DMSO) control was used for all chemicals. Statistically significant 
changes in percentage cells relative to the vehicle control are denoted 
by *, where *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Arrows above 
selected concentrations correspond to the MN LOEL for carcinogens, 
where applicable
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distribution at 4  h (data not shown); therefore, a 23  h 
exposure with lower  H2O2 concentrations was completed 
(Fig. 4a). Lower concentrations were used for 23 h than 4 h, 
to prevent reductions in RPD exceeding 50%. Similarly to 
three of the GCs, the NGC  NiCl2 (Fig. 4e) caused G2 cell-
cycle arrest, with this being observed at all tested concentra-
tions (i.e., ≥ 100 µM). No significant alterations in cell-cycle 
were observed for the remaining NGCs (Fig. 4f–h).
The majority of chemicals caused cell and nuclear 
morphological changes
Cell morphological changes have previously been associated 
with metastasis and invasion (Grünert et al. 2003; Tsai and 
Yang 2013) and are the basis of CTAs. Metastasis is closely 
associated with cancer mortality in humans and invasion 
links to the epithelial to mesenchymal transition (EMT). 
Therefore, cell morphology may provide a powerful early 
indicator of carcinogenesis-associated alterations.
Three out of four GCs significantly altered cell area 
(Fig. 5) relative to the vehicle control. The NGCs gener-
ally gave a greater response for cell area than for nuclear 
area, which contrasted with some of the GC data. With 
the exception of TCDD, the NGCs caused a significant 
reduction in cell area, each significantly increasing the 
“Lowest”/”Smallest” cell category (Fig. 5e–g). The great-
est cell area decrease was observed with  NiCl2, which 
caused the percentage of cells < 137 µm2 to decrease by 
23% (Fig. 5e). TCDD (Figs. 5, 6h) was the only chemical 
that did not alter cell or nuclear area.
For nuclear area, a greater level of significance was gener-
ally observed for the GCs than for cell area (Figs. 5, 6, Sup-
plementary File 5). For example, MNU produced a highly 
significant (p < 0.0002) increase in nuclei of > 90.1 µm2 
from 19 to 38%.  H2O2 caused the “Smallest” range of the 
nuclei (Fig. 6a) (< 95 µm2) to increase more than three-
fold, from 20 to 64%. In addition, acetaldehyde did not have 
any significant effect on cell area whilst a significant, 5% 
decrease of “Small” sized nuclei was observed. The extent 
of statistical significance for the two morphology endpoints 
is summarised in Fig. 6.
Bioenergetics analysis revealed trends for carcinogens
Mitochondrial and glycolytic flux were measured using 
the Seahorse  XFe24 Analyzer (Fig.  7) to determine 
whether carcinogens influenced cellular bioenergetic 
profiles. Figure 7 models the shift from vehicle controls 
towards “stressed” phenotypes following chemical treat-
ment (Robinson et al. 2012). Although no changes were 
significant, general trends were apparent. MNU, MC and 
acetaldehyde induced a shift towards an “energetic” phe-
notype.  NiCl2, DEHP and MMS shifted cells towards qui-
escence, reducing both OCR and ECAR.  NiCl2 reduced 
OCR by almost threefold at 150 µM, from 459 pmol/min 
to 156.8 pmol/min, while simultaneously reducing ECAR 
by 1.8-fold. Interestingly,  NiCl2 also elevated ROS con-
centrations, as mentioned previously (Supplementary File 
5).  H2O2 caused a more glycolytic phenotype, whereas 
TCDD demonstrated contrasting trends at different 
concentrations.
Endpoints were summarized using the ToxPi GUI
To visualise trends for different endpoints and to rank 
the chemicals in terms of their toxicological impact, 
ToxPi GUI was used to generate a diagrammatical rep-
resentation for each chemical (Fig. 8). Composite scores 
for all endpoints were generated for each chemical, in an 
attempt to predict their rank order in terms of carcino-
genic effects.
In terms of the ToxPi profiles, the GCs produced 
broadly similar distributions, altering similar endpoints, 
in particular p53, phospho-p53, cell-cycle distribution, cell 
and nuclear area, and MN frequency. Within the five high-
est-ranking scores, four of these were GCs, with scores 
ranging from 60.2 for MNU to 36.5 for acetaldehyde. 
Meanwhile,  H2O2 produced a score of 52.7 and MMS, 
40.7. It is important to note that  H2O2 was the only chemi-
cal where endpoints were measured at 4 h, rendering it the 
most potent compound overall despite not achieving the 
greatest score.
NGCs generally produced the lowest scores, with three 
ranking 6th–8th, as follows: MC (29.2),  NiCl2 (27.1) and 
DEHP (26.4). This complemented the fact that NGCs 
altered fewer carcinogenicity endpoints than GCs. The 
ToxPi profiles displayed noticeable similarities between 
these three chemicals, despite p21, p53 and cell-cycle 
arrest being induced by  NiCl2 only. TCDD, however, elic-
ited a greater effect than other NGCs, producing the third 
highest score (42.3). This high rank was almost entirely 
due to the large gene expression increases induced by 
TCDD, as this chemical did not alter any other endpoints. 
As a result, TCDD’s ToxPi profile indicates a somewhat 
unique response compared to other chemicals, differing 
from that of either carcinogen group.
Furthermore, the ToxPi profiles and accompanying rank 
order demonstrated potential for read-across between car-
cinogen classes, indicating some separation between GCs 
and NGCs, with GCs generally inducing greater responses 
for these endpoints.
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Discussion
The accurate prediction of a novel chemical’s carcinogenic 
potential in humans is crucial if cancer prevention is to be a 
possibility. Analysis of phenotypic changes of human cells in 
response to carcinogens is essential for fully understanding 
human oncogenesis. Holistic testing of carcinogens offers 
many advantages over the testing of isolated endpoints 
(Benigni 2014; Bourcier et al. 2015; Breheny et al. 2011; 
McKim and James 2010), ranging from improved predictiv-
ity to reduced time and financial costs (Kirsch-Volders et al. 
1997; Stankowski et al. 2015). The use of in vitro testing 
approaches and chemical mode-of-action identification is 
currently favoured (Adeleye et al. 2015; EPA 2005; Thy-
baud et al. 2007). Indeed, many mechanism-centric in vitro 
tests using “next generation” approaches for identifying 
Fig. 5  Violin plots displaying 
cell area changes within data 
obtained via the INCell Ana-
lyzer, followed by Matlab-based 
image analysis. The frequency 
of cells (%) in each quintile 
category is plotted. The cell 
area ranges represented by the 
quintiles are included in Sup-
plementary File 2. Alterations 
of the percentage of cells/nuclei 
within these set ranges were 
compared following treatment 
with carcinogens. Statisti-
cally significant changes in 
percentage cells relative to the 
vehicle control are denoted by 
*, where *p ≤ 0.05, **p ≤ 0.01 
and ***p ≤ 0.001. These are 
summarised in Supplementary 
File 3. No recovery time (i.e., 
0 h) was allowed following the 
treatment period, due to data 
collection at 8 and 23 h recover-
ies consistently demonstrating 
reduced effects on morphology 
compared to 0 h. Other mor-
phology endpoints, such as cell 
and nuclear perimeter, solidity 
and form factor were also deter-
mined using the script-based 
analysis method, increasing 
confidence in the cell and 
nuclear area changes observed 
(colour figure online)
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carcinogens have been developed (Caiment et al. 2013; 
Gusenleitner et al. 2014; Herwig et al. 2016; Tilton et al. 
2015), with these linking to cancer hallmarks or toxicity pri-
oritisation (Dix et al. 2007; Kleinstreuer et al. 2012; Smith 
et al. 2016).
This study’s objective was to further develop such 
approaches, determining whether the carcinogenic 
potential of known in vivo carcinogens could be success-
fully identified via an in vitro, multi-endpoint test system, 
with particular interest in identifying NGCs. Ten molec-
ular and cellular “surrogate” carcinogenicity endpoints 
reflecting the “Hallmarks of Cancer” (Hanahan and Wein-
berg 2011) were selected to test eight carcinogens.
Fig. 6  a Graphical summary of the total number of quintiles pro-
ducing statistically significant changes relative to the untreated con-
trol for the two different morphological endpoints: cell area (Fig. 5) 
and nuclear area (Supplementary File 5). Inset: Example images of 
randomly selected “small”, “medium” and “large” cell and nuclear 
images captured using the INCell Analyzer 2000. b Colour-coded 
cell and nuclear perimeters overlaid on randomly selected raw images 
obtained via the INCell Analyzer, to illustrate an increase in cell 
(black outlines) and nuclear (white outlines) area (µm2) following 
13.6 µM MMS treatment (colour figure online)
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Multi‑endpoint analysis provided more informative risk 
assessment
A flow diagram was created to summarise the relationships 
between the endpoints, or “adverse outcomes” (Supple-
mentary File 6), based on the data. Generally, similar trends 
for the GCs were apparent for p53, p21 and the cell-cycle, 
reflecting the outcomes of studies such as (Lukas et al. 
2004). Cell morphology, however, indicated some diver-
sity in trends for GCs: MMS and MNU increased cell and 
nuclear area, in agreement with relative cellular size at G2 
phase (Figs. 5, 6). In contrast,  H2O2 markedly reduced cell 
and nuclear area (Figs. 5, 6), possibly linking to its shorter 
exposure duration (4 h). However, this also reflects some 
NGC trends, perhaps suggesting a ROS-centric mechanism 
(Stannard et al. 2016). It was hypothesised that the mam-
malian target of rapamycin (mTOR) may orchestrate cell 
morphology alterations (Fumarola et al. 2005; Llanos et al. 
2016; Pincus and Theriot 2007). Indeed, we have noted that 
mTOR-inhibitor rapamycin reduced cell and nuclear area, 
indicating effects similar to some test carcinogens (Sup-
plementary File 7). In general, NGCs induced fewer sig-
nificant effects than GCs, with  these mainly involving gene 
expression and cell morphology alterations (Figs. 3, 5, 6, 
Supplementary File 6). No significant effects were observed 
for bioenergetics, which may be unsurprising when using 
low-doses; however, this endpoint remains valuable for car-
cinogenicity testing. The use of holistic endpoints could be 
considered synonymous with “key events” of the Adverse 
Outcome Pathway (AOP) concept. However, the present 
approach avoids the limitations of focusing on a single path-
way, as a combination of both molecular- and cellular-level 
changes are considered.
Data for the multiple endpoints could, with further opti-
misation, be multiplexed within a single, high-content sys-
tem, such as the INCell Analyzer. For example, MN and 
cell-cycle data can already be collected simultaneously 
via this approach. Furthermore, while endpoints were 
selected based on their relationship to the “Hallmarks of 
Cancer”, one of the major original hallmarks, resistance 
Fig. 7  Bioenergetics analysis 
of control and treated cells 
using the Seahorse  XFe24 
Bioanalyzer (n ≥ 3) to establish 
whether chemicals induced a 
“stressed” phenotype. OCR 
is plotted against ECAR for 
basal cellular metabolic rates. 
Historical vehicle controls 
 (H2O, DMSO) are included and 
blue points correspond to  H2O 
chemicals, whereas red points 
correspond to DMSO chemi-
cals. Green points correspond 
to TCDD, which was analysed 
in a different cell line (MCL-5). 
Cluster analysis was performed 
on the data. Four bioenergetic 
states were included [Quiescent, 
aerobic (oxidative phosphoryla-
tion), glycolytic and energetic 
(glycolytic + oxidative phos-
phorylation)] that represent the 
energy phenotype (colour figure 
online)
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to apoptosis, was not included. This is due to the low con-
centrations of chemical used inducing only minimal levels 
of apoptosis, meaning that resistance to apoptosis would 
be difficult to measure effectively.
Another important aspect of validation relates to “non-
carcinogens”, as it is necessary to ensure that such chemi-
cals deliver negative results. Extensive validation of this 
class is beyond the scope of the present study. However, 
the vehicles used,  H2O and DMSO, are non-carcinogens 
and did not adversely alter the endpoints tested. The lack 
of effect for these chemicals provided support for the 
assay’s specificity.
The CBMN assay exhibited limited sensitivity 
for detecting carcinogenic outcomes
Importantly, for the GCs, alterations in other, non-MN end-
points (Figs. 3, 4) often occurred at concentrations lower 
than the LOEL for MN frequency. This suggests that other, 
non-genotoxicity endpoints offer greater sensitivity for GC 
detection than the CBMN assay. This may be due to the 
efficient removal of potentially clastogenic DNA lesions via 
DNA repair mechanisms at low doses; should such lesions 
remain unrepaired, these may also not necessarily cause the 
“late” cellular events that are MN (Fenech 1997). These 
protective factors reduce the frequency of observed clasto-
genic events (e.g., MN), and so the full DNA damage profile 
induced by the chemical may not be evident. The fact that 
the CBMN assay is not designed to detect NGCs further 
supports the use of multi-endpoint testing, particularly con-
sidering NGCs’ diverse mechanisms.
Importantly, all chemicals caused at least one statisti-
cally significant change in the endpoints tested; this again 
supports the use of multiple endpoint tests, as these may 
reduce the probability of “missing” biological impacts of 
carcinogens. No chemicals exhibited adverse effects at all 
concentrations tested for all endpoints, with low concentra-
tions, unsurprisingly, being less likely to induce an effect.
Discrete categories of carcinogens may be irrelevant: 
 NiCl2 exhibited GC‑like effects
While this study has provided mechanistic insights for indi-
vidual carcinogens (Supplementary File 6), the overall, 
integrated results for chemicals were also informative. The 
resulting scores (Fig. 8), when ranked from highest to low-
est, indicated a general separation between GCs and NGCs, 
with four of the five highest scores belonging to GCs. How-
ever, despite GCs and NGCs potentially affecting different 
endpoints, the incomplete separation between these groups 
suggested that carcinogens should be analysed on a case-
by-case basis. Therefore, this study proves that dividing 
carcinogens into discrete categories such as “genotoxic” 
and “non-genotoxic” may be an oversimplification, a case 
in point being  NiCl2.  NiCl2 conferred several effects that 
overlapped with those of GCs, such as p53 activation and G2 
cell-cycle arrest, despite not being observed to induce geno-
toxicity in this study (Fig. 1) or in some other studies (Big-
gart and Costa 1986; Chakrabarti et al. 2001). Therefore, 
 NiCl2 may not be a true NGC, as was previously believed, 
and its genotoxicity may be dependent on its exposure time 
(Stannard et al. 2016). It is, therefore, apparent that different 
groups of carcinogens have a unique in vitro “fingerprint” 
or “signature” for carcinogenicity. This could be termed the 
“Integrated Signature of Carcinogenicity” (ISC), represent-
ing the overall, multiple-endpoint response of cells in vitro 
Fig. 8  Outputs from the Toxicological Prioritization Index (ToxPi) 
GUI summarising the fold changes for the endpoints at the 50% RPD-
inducing concentration. Broken lines indicate the position of “one-
fold” for the relevant endpoints. Carcinogens were ranked according 
to their potency scores, from highest to lowest. Fold changes were 
square rooted, transformed and weighted as appropriate (i.e., 3 for 
each of “MN” and “Seahorse”, 1.5 for each of “cell area”, “nuclear 
area”, “p53″ and “phospho-p53”, and 1 for each of the remaining 
endpoints), and values < onefold were inverted to give values > one-
fold (for down-regulation). The sum all values for all endpoints was 
taken for each chemical, generating a final overall score. Data were 
scaled to provide three separate groups of “onefold” magnitude, due 
to notable variation in the magnitude of changes for different end-
points and, therefore, to ensure clear visualisation of all endpoint 
“slices” (colour figure online)
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to any test chemical (Fig. 8). With further validation, it is 
possible that a “cut-off” ISC value could be identified, ena-
bling GCs to be distinguished from NGCs.
In vitro and in vivo rankings were broadly aligned
Relating rank order, or ISCs, to in vivo carcinogenicity 
data may be informative, particularly as such an approach 
may replace the two-year rodent carcinogenicity bioassay 
for non-pharmaceuticals, impacting on the chemical indus-
try.  TD50 data for the chemicals (Gold database) are listed 
below:
TCDD: 0.000023 mg/kg/day; rat
MNU: 0.0927 mg/kg/day; rat
MMS: 32 mg/kg/day; mouse
MC: 56 mg/kg/day; rat
Acetaldehyde: 153 mg/kg/day; rat
DEHP: 716 mg/kg/day; rat
H2O2: 7,540 mg/kg/day; mouse
NiCl2: Data unavailable
The in vitro and in vivo data indicated broad agree-
ment: three of the four most potent in vivo carcinogens, 
based on these chemicals’  TD50 doses, corresponded 
with the ToxPi rankings for the 50% RPD concentra-
tions, despite a slightly different ranking order; however, 
 H2O2 appears to be considerably less potent in  vivo, 
being ranked last. Interestingly,  H2O2 was the most potent 
chemical in vitro, being the only chemical to induce gen-
otoxicity after 4 h while producing the second highest 
ToxPi score. This difference could be explained by the 
greater antioxidant capacity in vivo (Niki 2010) compared 
to in vitro systems, which are known to be hyperoxic and 
devoid of protective antioxidants. Another explanation 
may relate to the in vivo method of exposure being via the 
animals’ water, contributing to losses of unstable  H2O2 
to, for example, digestive system microbiota. The highest-
ranking in vivo carcinogen was TCDD, whereas in vitro, 
GCs ranked higher.
Conclusions
The present study has established that a multiple-endpoint 
approach is a more comprehensive means of assessing car-
cinogenicity of environmental carcinogens in vitro than 
traditional, single-endpoint tests. Crucially, this novel test-
ing strategy will provide a means of in vitro NGC detec-
tion. Advantages of our approach include use of low-doses, 
automated technology and genetically stable human cells. 
Such a test could eventually provide sufficient informa-
tion to replace the two-year rodent carcinogenicity assay 
for non-pharmaceuticals, reducing animal use in carcino-
genicity assessment. Further data for other chemicals and 
cell models, such as liver, are now required to verify these 
observations.
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